Flagship’s Omega fuels RNA-encoded, genomic structure-targeting pipeline with $126M series C

Omega is pushing further into the white space of targeting 3-D genomic structures via a $126 million series C round, with a crossover syndicate joining founding investor Flagship Pioneering.

Mahesh Karande,  Omega Therapeutics Inc.’s president and CEO, told BioCentury that while the company’s lipid nanoparticle (LNP)-delivered, mRNA-encoded candidates benefit from the “halo effect” of successful COVID-19 vaccines, the core of the company’s approach is the genomic structures it targets, not its therapeutic modality. ...